Abstract
Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.
| Original language | English (US) |
|---|---|
| Journal | BMJ (Online) |
| Volume | 364 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Circulating high sensitivity C reactive protein concentrations and risk of lung cancer : Nested case-control study within Lung Cancer Cohort Consortium. / Muller, David C.; Larose, Tricia L.; Hodge, Allison; Guida, Florence; Langhammer, Arnulf; Grankvist, Kjell; Meyer, Klaus; Cai, Qiuyin; Arslan, Alan A.; Zeleniuch-Jacquotte, Anne; Albanes, Demetrius; Giles, Graham G.; Sesso, Howard D.; Lee, I. Min; Gaziano, J. Michael; Yuan, Jian Min; Bolton, Judith Hoffman; Buring, Julie E.; Visvanathan, Kala; Le Marchand, Loic; Purdue, Mark P.; Caporaso, Neil E.; Midttun, Øivind; Ueland, Per M.; Prentice, Ross L.; Weinstein, Stephanie J.; Stevens, Victoria L.; Zheng, Wei; Blot, William J.; Shu, Xiao Ou; Zhang, Xuehong; Xiang, Yong Bing; Koh, Woon Puay; Hveem, Kristian; Thomson, Cynthia A.; Pettinger, Mary; Engström, Gunnar; Brunnström, Hans; Milne, Roger L.; Stampfer, Meir J.; Han, Jiali; Johansson, Mikael; Brennan, Paul; Severi, Gianluca; Johansson, Mattias.
In: BMJ (Online), Vol. 364, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Circulating high sensitivity C reactive protein concentrations and risk of lung cancer
T2 - Nested case-control study within Lung Cancer Cohort Consortium
AU - Muller, David C.
AU - Larose, Tricia L.
AU - Hodge, Allison
AU - Guida, Florence
AU - Langhammer, Arnulf
AU - Grankvist, Kjell
AU - Meyer, Klaus
AU - Cai, Qiuyin
AU - Arslan, Alan A.
AU - Zeleniuch-Jacquotte, Anne
AU - Albanes, Demetrius
AU - Giles, Graham G.
AU - Sesso, Howard D.
AU - Lee, I. Min
AU - Gaziano, J. Michael
AU - Yuan, Jian Min
AU - Bolton, Judith Hoffman
AU - Buring, Julie E.
AU - Visvanathan, Kala
AU - Le Marchand, Loic
AU - Purdue, Mark P.
AU - Caporaso, Neil E.
AU - Midttun, Øivind
AU - Ueland, Per M.
AU - Prentice, Ross L.
AU - Weinstein, Stephanie J.
AU - Stevens, Victoria L.
AU - Zheng, Wei
AU - Blot, William J.
AU - Shu, Xiao Ou
AU - Zhang, Xuehong
AU - Xiang, Yong Bing
AU - Koh, Woon Puay
AU - Hveem, Kristian
AU - Thomson, Cynthia A.
AU - Pettinger, Mary
AU - Engström, Gunnar
AU - Brunnström, Hans
AU - Milne, Roger L.
AU - Stampfer, Meir J.
AU - Han, Jiali
AU - Johansson, Mikael
AU - Brennan, Paul
AU - Severi, Gianluca
AU - Johansson, Mattias
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.
AB - Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.
UR - http://www.scopus.com/inward/record.url?scp=85059500268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059500268&partnerID=8YFLogxK
U2 - 10.1136/bmj.k4981
DO - 10.1136/bmj.k4981
M3 - Article
C2 - 30606716
AN - SCOPUS:85059500268
VL - 364
JO - The BMJ
JF - The BMJ
SN - 0959-8146
ER -